Results 151 to 160 of about 23,808 (216)

The Early Evolution of Population II Stars

The Astrophysical Journal, 1967
openaire   +1 more source

Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha, Bishwas Mandal, Vishal Mandal, Asis Shrestha, Amir Babu Shrestha   +4 more
wiley   +1 more source

Arrhythmic risk in mitral valve prolapse with mitral annular disjunction: meta-analysis of longitudinal studies. [PDF]

Sci Rep
Chianese S, Ordine L, Pacella D, Canciello G, Di Napoli S, Lombardi R, Esposito G, Losi MA.   +7 more
europepmc   +1 more source

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Mental health outcomes in patients with inherited retinal diseases: a systematic review and meta-analysis. [PDF]

Int J Retina Vitreous
Abu Serhan H, Ahmed A, Sbei O, Kojan W, Chaudhry M, Khalid M, Sheraz A, Al-Moujahed A.   +7 more
europepmc   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, EarlyView.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

The second survey of the Saudi Acute Myocardial Infarction Registry Program: Main results and temporal changes in care (STARS-2 program). [PDF]

PLoS One
AlSaleh A, AlSaif SM, Alhadramy O, Alshehri M, Al Faraidy K, Almutairi F, Kinsara AJ, Al-Murayeh M, Ghabashi AE, Alasnag M, Hussein GA, Askar TM, Haider KH, Alharbi IA, Almokhlef A, Sayed BA, Almasswary A, Ul-Sabah Z, Kazim H, Albareda HA, Aldossari MA, Albawardi R, Alali R, Abdulhabeeb IAM, Ibrahim SM, Alasmari S, Almoghairi AM, Khoja AY, Hussain N, Aminu BS, Serafi A, Eltayeb AO, BuSaleh AH, Alsabatien B, Hamza MK, Alsharkawy R, Awwad AA, Mohamed MA, Al Habeeb MA, Shujauddin S, Ya'u JA, Attia NM, Kholaif N, Bin Ghouth NM, Youssef MKI, Qutub MA, Lawand SR, Alkutshan R, Ahmed E, Basardah A, Alhaj WI, Altaradi H, Ali M, Alqarawi W, Alhabib KF, STARS-2 Investigators.   +55 more
europepmc   +1 more source

Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer

Aging and Cancer, EarlyView.
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss, Alexis C. Wardell, Allison M. Deal, Kirsten A. Nyrop, Allison Ross, Yara G. Abdou, Jeffrey D. Aldrich, Lisa A. Cary, E. Claire Dees, Katherine E. Reeder‐Hayes, Emily M. Ray, Natalia Mitin, Denis Tsygankov   +12 more
wiley   +1 more source

Associations of three immune inflammatory markers with the risk of brain metastasis from lung cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Liu M, Shi Y, Chen A, Hu X.
europepmc   +1 more source

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source